Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.

medRxiv : the preprint server for health sciences·2026
Same author

Study partner profile effects on CDR-SB change in anti-amyloid therapy evaluation.

medRxiv : the preprint server for health sciences·2026
Same author

Potential and biases of large language model simulation for public surveys on Alzheimer's disease therapies.

Journal of Alzheimer's disease : JAD·2026
Same author

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS).

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Mapping U.S. POINTER Cognitive-Slope Gains Onto Predicted Clinical Progression: An External-Cohort Translation Analysis With Exploratory Economic Thresholds.

medRxiv : the preprint server for health sciences·2026
Same author

Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Takeshi Iwatsubo1

  • 1Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括

在氨酸217 (p-tau217) 和Aβ生物标志物中酸化的血精确预测早期阿尔茨海默病 (AD) 中的粉样蛋白PET阳性. 这些血液检测可以帮助对临床试验的患者进行查,并监测治疗的有效性.

科学领域:

  • 神经学 神经学
  • 生物标志物发现发现
  • 阿尔茨海默氏症疾病研究研究

背景情况:

  • 迫切需要血生物标志物来预测早期阿尔茨海默病 (AD) 中的粉样PET阳性.
  • 评估氨酸217 (p-tau217) 化的血的有用性,用于预测粉样蛋白PET状态.
  • 评估血生物标志物在监测AD疾病修饰疗法 (DMT) 中的作用.

研究的目的:

  • 确定血p-tau217和Aβ生物标志物在预测粉样PET阳性的准确性.
  • 研究血生物标志物和临床信息在预测Aβ-PET状态方面的联合实用性.
  • 评估血生物标志物的潜力,以预先选患者,并监测AD中的DMT疗效.

主要方法:

  • 利用了日本临床前/临床前AD (J-TRC) 准备试验的队列,其中包括474名非痴呆症患者.
  • 评估参与者使用粉样蛋白PET (florbetapir或flutemetamol) 和血生物标志物测试 (p-tau217,Aβ42,Aβ40).
  • 使用IP质谱和免疫测试平台测量了等离子体生物标志物.

主要成果:

  • 血p-tau217在检测异常的Aβ-PET扫描中表现出高精度 (AUC = 0.913).
  • 血Aβ42/40比率在预测Aβ-PET阳性方面也显示出高准确度 (AUC = 0.856).

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699
  • 将血生物标志物 (p-tau217/Aβ42比率) 与临床信息 (APOE,年龄,性别) 结合在一起的模型实现了最高的AUC (高达0.955).

    • 结论:

    • 单独或与Aβ生物标志物结合的血p-tau217有效地预测了临床前和临床前AD的Aβ-PET阳性.
    • 血p-tau217测定显示出预先选患者进行临床试验的前景.
    • 这些等离子体测定用于监测抗Aβ抗体和其他DMT疗效的实用性正在现实环境中进行评估.